A surge of clinical trials with great potential for promising new treatments for T-cell lymphoma are based on significant basic research momentum made possible by a number of scientists and researchers, reports Dana-Farber Cancer Institute’s Insight blog.
A form of non-Hodgkin lymphoma (NHL), T-cell lymphoma occurs when immune system T cells begin growing and multiplying uncontrollably. With numerous types of the disease in all the entire group of them account for about 10% of NHL cases in America.
A group of new studies, some opened, some expected to open soon and some completed, represents a major thrust against the disease.
Back in 2015, Dana Farber’s David Weinstock, MD, led researchers at several institutions in receiving a prestigious SCOR (Specialized Center of Research) grant from the Leukemia and Lymphoma Society to support collaborative research into the disease. The grant was awarded to scientists at not only Dana-Farber but also other institutions and has underwritten research in laboratory cell lines and animal models and set the stage for the new wave of clinical research now underway.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).